SMC endorses Alexion’s Ultomiris
Committee also accepted Braftovi combination, Ledaga and Zejula for use by NHS Scotland in May decisions
Read More
Tag: Braftovi
NICE backs Braftovi for BRAF-positive colorectal cancer
Positive recommendation follows initial rejection in September
Read More
NICE no for Pierre Fabre’s Braftovi
Preliminary guidelines reject NHS funding for the drug for BRAF V600E mutation-positive metastatic colorectal cancer
Read More
EU nod for new metastatic colorectal cancer combination
Pierre Fabre’s Braftovi in combination with Erbitux is the first licensed therapy for a specific subset of colorectal cancer patients
Read More
HSE reimburses Braftovi combo
Eligible patients in the Republic of Ireland can potentially benefit from the combination with immediate effect.
Read More
NICE OK for Braftovi skin cancer drug
The National Institute for Health and Care Excellence (NICE) has recommended Pierre Fabre’s Braftovi and Mektovi combination as an option for some people with melanoma.
Read More
EU approves new option for metastatic melanoma
The European Commission (EC) has granted marketing authorisation for Pierre Fabre’s Braftovi and Mektovi combination therapy for the treatment of adults with unresectable or metastatic melanoma with a BRAFV600 mutation.
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
